ImmuPharma PLC (IMM) — Strategic Asset Allocation Index
ImmuPharma PLC (IMM) has a Strategic Asset Allocation Index of 19.2% as of June 2023. Strategic assets (PP&E of GBX332.99K plus long-term investments of GBX-) total GBX332.99K, measured against net assets of GBX1.74 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check IMM cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
ImmuPharma PLC Strategic Asset Allocation Index (2006–2021)
This chart shows how ImmuPharma PLC's Strategic Asset Allocation Index has evolved across 17 annual periods from 2006 to 2021. As of June 2023, the index stands at 19.2%, representing strategic assets of GBX332.99K against net assets of GBX1.74 Million GBX. See IMM free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for ImmuPharma PLC (2006–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for ImmuPharma PLC from 2006 to 2021, covering 17 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is ImmuPharma PLC worth.
| Year | SAAI | Strategic Assets (GBX) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 8.0% | GBX353.00K | GBX353.00K | GBX- | GBX4.41 Million | ▲ +3.7 pp |
| 2020 | 4.3% | GBX411.61K | GBX411.61K | GBX- | GBX9.65 Million | ▲ +0.3 pp |
| 2019 | 3.9% | GBX206.74K | GBX206.74K | GBX- | GBX5.27 Million | ▼ -24.5 pp |
| 2018 | 28.4% | GBX2.16 Million | GBX164.66K | GBX2.00 Million | GBX7.62 Million | ▲ +23.9 pp |
| 2017 | 4.5% | GBX161.40K | GBX161.40K | GBX- | GBX3.57 Million | ▲ +0.3 pp |
| 2016 | 4.2% | GBX231.90K | GBX231.90K | GBX- | GBX5.55 Million | ▼ -12.4 pp |
| 2015 | 16.6% | GBX280.13K | GBX280.13K | GBX- | GBX1.69 Million | ▲ +10.2 pp |
| 2014 | 6.4% | GBX366.00K | GBX366.00K | GBX- | GBX5.71 Million | ▲ +4.6 pp |
| 2013 | 1.8% | GBX97.00K | GBX97.00K | GBX- | GBX5.40 Million | ▲ +0.4 pp |
| 2012 | 1.4% | GBX115.00K | GBX115.00K | GBX- | GBX8.42 Million | ▲ +0.4 pp |
| 2011 | 1.0% | GBX125.00K | GBX125.00K | GBX- | GBX12.51 Million | ▲ +0.5 pp |
| 2010 | 0.5% | GBX77.00K | GBX77.00K | GBX- | GBX15.97 Million | ▲ +0.4 pp |
| 2009 | 0.0% | GBX9.00K | GBX9.00K | GBX- | GBX18.08 Million | ▼ -0.1 pp |
| 2008 | 0.1% | GBX13.00K | GBX13.00K | GBX- | GBX11.24 Million | ▼ -0.3 pp |
| 2007 | 0.4% | GBX13.00K | GBX13.00K | GBX- | GBX3.05 Million | ▲ +0.2 pp |
| 2006 | 0.2% | GBX12.00K | GBX12.00K | GBX- | GBX5.89 Million | ▼ -0.3 pp |
| 2006 | 0.5% | GBX12.00K | GBX12.00K | GBX- | GBX2.50 Million | — |